<DOC>
	<DOCNO>NCT02528214</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy dupilumab , compare placebo , reduce use maintenance oral corticosteroid ( OCS ) patient severe steroid-dependent asthma . Secondary Objectives : - To evaluate safety tolerability dupilumab . - To evaluate effect dupilumab improve patient-reported outcome . - To evaluate dupilumab systemic exposure incidence treatment-emergent antidrug antibody .</brief_summary>
	<brief_title>Evaluation Dupilumab Patients With Severe Steroid Dependent Asthma</brief_title>
	<detailed_description>The total study duration per patient 46 week , consist screen period 3 8 week ( 10 week patient experience clinically significant asthma exacerbation screen period ) , randomize treatment period 24 week , post-treatment period 12 week . Patients complete treatment consider eligibility long term extension study LTS12551 .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Inclusion criterion : Adult adolescent ( 12 year age old ) patient physician diagnosis asthma ≥12 month , base Global Initiative Asthma ( GINA ) 2014 guideline follow criterion : Patients severe asthma welldocumented , regular prescribe treatment maintenance corticosteroid 6 month prior Visit 1 use stable OCS dose ( ie , change OCS dose ) 4 week prior Visit 1 . Patients must take 5 35 mg/day prednisone/prednisolone , equivalent , Visit 1 Randomization visit . In addition , patient must agree switch studyrequired prednisone/prednisolone OCS use per protocol duration study . Existing treatment highdose inhale corticosteroid ( ICS ; &gt; 500 mcg total daily dose fluticasone propionate equivalent ) combination second controller ( ie , longacting beta agonist [ LABA ] , leukotriene receptor antagonist [ LTRA ] ) least 3 month stable dose ICS ≥1 month prior Visit 1 . In addition , patient require third controller asthma consider eligible study , also use least 3 month stable dose ≥ 1 month prior Visit 1 . A forced expiratory volume 1 second ( FEV1 ) &lt; 80 % predict normal adult ≤90 % predict normal adolescent Visit 1 . Evidence asthma document either : reversibility least 12 % 200 mL FEV1 administration 200 400 mcg ( 2 4 inhalation albuterol/salbutamol levalbuterol/levosalbutamol , nebulized solution albuterol/salbutamol levalbuterol/levosalbutamol , consider standard office practice ) randomization document 12 month prior Visit 1 OR airway hyperresponsiveness ( methacholine : provocative concentration cause positive reaction [ PC20 ] &lt; 8 mg/mL ) document 12 month prior Visit 1 . Exclusion criterion : Patients &lt; 12 year age minimum legal age adolescent country investigative site , whichever high ( country local regulation permit enrollment adult , subject recruitment restrict ≥18 year age ) . Patients weigh &lt; 30.0 kg . Chronic obstructive pulmonary disease ( COPD ) lung disease ( eg , idiopathic pulmonary fibrosis , ChurgStrauss Syndrome , allergic bronchopulmonary aspergillosis , cystic fibrosis ) may impair lung function . Clinical evidence imaging ( eg , chest Xray , compute tomography , magnetic resonance imaging ) within 12 month Visit 1 clinically significant finding lung disease ( ) asthma , per local standard care . A patient experience deterioration asthma result emergency treatment hospitalization within 4 week Screening Visit 1 . A patient require 12 puff rescue medication 1 day week prior Visit 1 . A subject experience upper low respiratory tract infection within 4 week prior screen . Current smoker cessation smoking within 6 month prior Visit 1 . Previous smoker smoke history &gt; 10 packyears . Comorbid disease might interfere evaluation investigational medicinal product . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>